Thrivent Financial for Lutherans increased its position in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 108.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 74,625 shares of the biopharmaceutical company's stock after buying an additional 38,876 shares during the quarter. Thrivent Financial for Lutherans owned about 0.12% of Sage Therapeutics worth $405,000 at the end of the most recent reporting period.
A number of other large investors have also recently added to or reduced their stakes in the business. Intech Investment Management LLC purchased a new stake in Sage Therapeutics in the third quarter valued at $146,000. Charles Schwab Investment Management Inc. raised its holdings in Sage Therapeutics by 10.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 452,193 shares of the biopharmaceutical company's stock valued at $3,265,000 after buying an additional 43,617 shares during the period. BNP Paribas Financial Markets lifted its position in Sage Therapeutics by 52.2% in the third quarter. BNP Paribas Financial Markets now owns 70,986 shares of the biopharmaceutical company's stock valued at $513,000 after buying an additional 24,356 shares during the last quarter. Erste Asset Management GmbH acquired a new position in Sage Therapeutics in the third quarter valued at about $208,000. Finally, RTW Investments LP boosted its stake in Sage Therapeutics by 2.0% during the third quarter. RTW Investments LP now owns 5,591,700 shares of the biopharmaceutical company's stock worth $40,372,000 after buying an additional 111,123 shares during the period. 99.22% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several equities analysts have recently commented on the stock. Scotiabank decreased their price objective on shares of Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating on the stock in a report on Wednesday, February 12th. Wedbush restated a "neutral" rating and set a $6.00 price target on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Canaccord Genuity Group lowered their price target on Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating for the company in a research report on Wednesday, February 12th. Stifel Nicolaus cut their price objective on Sage Therapeutics from $10.00 to $6.00 and set a "hold" rating on the stock in a report on Monday, December 16th. Finally, Piper Sandler lowered their target price on Sage Therapeutics from $26.00 to $9.00 and set an "overweight" rating for the company in a report on Thursday, January 2nd. Three equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat, Sage Therapeutics presently has an average rating of "Hold" and a consensus target price of $8.81.
View Our Latest Analysis on SAGE
Sage Therapeutics Stock Performance
Shares of NASDAQ:SAGE traded down $0.27 during trading hours on Tuesday, reaching $6.39. The stock had a trading volume of 1,343,955 shares, compared to its average volume of 1,247,647. The stock has a market capitalization of $392.86 million, a price-to-earnings ratio of -0.97 and a beta of 0.48. The firm's 50 day moving average is $7.48 and its 200-day moving average is $6.71. Sage Therapeutics, Inc. has a 1 year low of $4.62 and a 1 year high of $17.05.
Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. Analysts forecast that Sage Therapeutics, Inc. will post -3.52 EPS for the current year.
Sage Therapeutics Profile
(
Free Report)
Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.
Featured Stories
Before you consider Sage Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sage Therapeutics wasn't on the list.
While Sage Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
